TP53 and hepatocellular carcinoma: The synergistic application of the stearoyl-CoA desaturase 1 (SCD1) inhibitor aramchol alongside the deuterated sorafenib derivative donafenib has shown significant anti-tumor efficacy in p53-wild type HCC organoids [59].